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ABSTRACT:
Grapefruit juice increases the oral availability of a variety of
CYP3A4 substrates. It has been shown that recurrent grapefruit
juice ingestion results in a loss of CYP3A4 from the small bowel
epithelium. We now show that the reduction in intestinal CYP3A4
concentration is rapid; a 47% decrease occurred in a healthy
volunteer within 4 hr after consuming grapefruit juice. To identify
the specific components of the juice responsible for this effect, we
used a recently developed Caco-2 cell culture model of human
intestinal epithelium that expresses catalytically active CYP3A4.
We found that grapefruit oil and two furanocoumarin constituents
(6*,7*-dihydroxybergamottin and a closely related dimer) caused a
dose-dependent fall in CYP3A4 catalytic activity and immunoreac-
tive CYP3A4 concentration. The effect was selective in that con-
centrations of CYP1A1 and CYP2D6 did not fall, consistent with
previous results obtained in vivo. Assays of various juices con-
firmed that 6*,7*-dihydroxybergamottin is the major furanocouma-
rin present and, although its concentration varies significantly
among types and brands of grapefruit juice, it is consistently
present in concentrations exceeding the IC50 (1 mM) for loss of
midazolam 1*-hydroxylase activity determined in the Caco-2 cells.
Studies with recombinant CYP3A4 revealed that 6*,7*-dihydroxy-
bergamottin is a mechanism-based inactivator, which supports the
idea that loss of CYP3A4 results from accelerated degradation of
the enzyme. We conclude that the effect of grapefruit juice on oral
availability of CYP3A4 substrates can be largely accounted for by
the presence of 6*,7*-dihydroxybergamottin although other furano-
coumarins probably also contribute.
Grapefruit juice has been reported to increase the oral availability
of a variety of CYP3A4 substrates including cyclosporin A (1),
felodipine (2), midazolam (3), terfenadine (4), verapamil (5), saquina-
vir (6), and ethinyl estradiol (7). Grapefruit juice has little effect on
intravenously administered drugs (1,3), however, and the primary
effect on orally administered drugs is to increase their peak serum
concentration (Cmax) with little change in the subsequent rate of
elimination as measured by half-life (2, 8). Therefore, it appears that
the grapefruit juice effect is at the level of the intestine and not the
liver. The grapefruit juice effect has been postulated to be the result of
competitive inhibition of CYP3A4 in the enterocytes lining the small
intestine (1, 2) because grapefruit juice has been shown to contain
substances capable of competitively inhibiting this enzyme (9–11).
However, in a recent study performed in healthy volunteers, consump-
tion of grapefruit juice for 6 days resulted in a mean 62% decrease in
enterocyte CYP3A4 immunoreactive protein concentration with no
change in CYP3A4 mRNA concentration (12). The magnitude of the
decrease in immunoreactive CYP3A4 correlated with the magnitude
of increase in felodipine AUC when the drug was taken with grape-
fruit juice instead of water (12). It was suggested that the effect may
be a result of a mechanism-based (“suicide”) inactivation of the
enzyme, followed by its rapid intracellular degradation (12).
Flavonoids, which are major constituents of grapefruit juice, are not
known to be mechanism-based inactivators. Naringin, the major fla-
vonoid present in grapefruit juice, and quercetin do not reproduce the
grapefruit juice effect when administered orally, also suggesting that
flavonoids are not the active compounds (8, 13). Edwards et al.
recently reported that 69,79-dihydroxybergamottin (DHB)1, a furano-
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coumarin present in grapefruit juice, is a potent inhibitor of CYP3A
enzymes in rat liver microsomes (14). Furanocoumarins are known
mechanism-based inactivators of cytochromes P450 (15, 16) and
might be responsible for the loss of intestinal CYP3A4 protein fol-
lowing grapefruit juice ingestion.
In this report, we show that the fall in CYP3A4 immunoreactive
protein in human enterocytes in vivo after grapefruit juice ingestion
occurs rapidly. A human intestinal epithelial cell line also exhibited a
rapid fall in CYP3A4 concentration when exposed to grapefruit oil.
We therefore used this culture model to test the hypothesis that
furanocoumarins are the major active ingredients in grapefruit juice.
Materials and Methods
Grapefruit, grapefruit juice, and frozen concentrated grapefruit juice were
obtained from local markets. DHB was synthesized from bergamottin (Ind-
ofine Chemical Company, Somerville, NJ) as described (14). One sample of
grapefruit oil was obtained from Berje´ (Bloomfield, NJ). A second sample of
grapefruit oil (Spectrum Chemical Manufacturing Corp., Garden, CA), R(1)-
and S(-)-limonene, decanal, and ketoconazole were gifts from Dr. Vincent
Wacher (AvMax, Berkeley, CA). Midazolam was received as a gift from Dr.
Bruce Mico (Roche Laboratories, Nutley, NJ). Isopropyl b-D-thiogalactoside
was purchased from Calbiochem Corp. (La Jolla, CA). NADPH, L-a-dilau-
royl- and L-a-dioleyl-sn-glycero-3-phosphocholines, phosphatidyl serine, tes-
tosterone, 6b- and 11b-hydroxytestosterone, catalase, glutathione, and d-
aminolevulinic acid hydrochloride and other chemicals were purchased from
Sigma Chemical Company (St. Louis, MO). NADPH-cytochrome P450 reduc-
tase and cytochrome b5 were purified from liver microsomes of phenobarbital
treated Long-Evans rats as previously described (17, 18). Microsomes were
prepared as described (19) from a human liver (HL4; medically unsuitable for
organ transplantation) that was obtained under the auspices of the Washington
Regional Transplant Consortium (Washington, DC).
Grapefruit Juice Fractionation. Grapefruit juice frozen concentrate (354
ml) was reconstituted with water to a final volume of 1 liter. The grapefruit
juice was then extracted with ten 100-ml portions of hexane, the organic layer
was dried with sodium sulfate, and the hexane was removed in vacuo. The
resulting residue was dissolved in ethanol, and the ethanol solution was
separated into fractions by a Hewlett-Packard (Wilmington, DE) 1090 HPLC
system. Grapefruit juice components were separated on a 4.6 x 150 mm M-80
C18 column (YMC, Wilmington, NC) that was eluted at 1 ml/min with a water
and acetonitrile gradient as follows: (time:% acetonitrile; 0:10; 5:10; 30:80;
40:80; 45:10; 50:10). The eluate was monitored at 260 nm and UV absorption
data were collected from 200–600 nm. All HPLC fractions were dried with a
Savant SpeedVac system (Farmington, NY) and stored at 280°C until used in
microsomal incubations.
Instrumental Analysis of Grapefruit Juice Fractions. Isolated grapefruit
juice fractions were analyzed further by LC/MS with a Hewlett-Packard 1050
HPLC system coupled to a Finnigan TSQ-7000 mass spectrometer operating in
the positive ion electrospray ionization (ESI) mode with the following oper-
ating conditions: ESI spray voltage, 4.5 kV; capillary temperature, 275°C;
auxiliary and sheath gas pressures, 5 and 65 psi, respectively. Conditions for
LC/MS/MS analyses operating in the daughter ion scan mode were as noted
and with a collision induced dissociation (CID) voltage of 260 eV and an
argon CID pressure of 1 mTorr. HPLC conditions for LC/MS analyses were as
noted previously except a 2.0 3 150 mm YMC M-80 C18 column was
substituted for the standard column and the flow rate was reduced to 0.2
ml/min.
Microsomal Incubations with Grapefruit Juice Fractions. Each of the
HPLC fraction residues was dissolved in 40 ml of ethanol, and 10 ml of these
solutions were added to 990 ml of human hepatic microsomal suspensions (0.5
mg/ml) that contained an NADPH regenerating system. Control incubations
contained the same concentration of ethanol but without grapefruit juice
fractions. The microsomes were incubated with 10 mM taxol for 30 min. Taxol
metabolites 6a-hydroxytaxol, a marker activity for CYP2C8, and taxol me-
tabolite B, a marker activity for CYP3A4, were quantitated as described
(19,20). Fraction 39 was subsequently studied more extensively. Using its
mass obtained from HPLC fractionation and its molecular weight based on
LC/MS/MS, microsomal incubations were prepared that contained either 0,
0.1, 0.5, 1, 5, or 10 mM fraction 39 and either 10, 20, or 50 mM taxol. After
30 min incubations, 6a-hydroxytaxol and taxol metabolite B were quantitated.
Quantitation of Bergamottin, DHB, 6*-Epoxybergamottin, and FC726
in Grapefruit, Grapefruit Juice, and Grapefruit Oil (data in table 1).
White grapefruit juice frozen concentrate (10 ml; Kroger) was diluted with
water to a final volume of 100 ml, 1 ml of 500 mM bergapten internal standard
was added, and the mixture was extracted with six 100-ml portions of chlo-
roform. The chloroform was removed in vacuo, and the resulting residue was
dissolved in methanol and analyzed with a Waters 600E HPLC system.
One white Florida grapefruit was halved, the fruit (juice vesicles only, not
the membranes surrounding the sections) was removed and homogenized in a
blender, and 1 ml of 500 mM bergapten internal standard was added. The
homogenate was extracted with six 100-ml portions of chloroform. The chlo-
roform was removed in vacuo, and the resulting residue was dissolved in
methanol and analyzed with a Waters 600E HPLC system.
Samples of cold-pressed grapefruit oil obtained from two sources were each
diluted 1/100 with methanol, and the resulting solutions were analyzed by
HPLC.
HPLC conditions for the quantitation of bergamottin, DHB, 69-
epoxybergamottin, and FC726 in the grapefruit juice, grapefruit homogenate,
and grapefruit oil were as noted above. Concentrations of bergamottin and
DHB were calculated from a standard curve for bergamottin based on the
assumption that bergamottin and DHB have the same extinction coefficient.
Concentrations of FC726 were determined from a standard curve for berga-
mottin based on the assumption that the extinction coefficient of FC726 is
twice that of bergamottin. The above assumptions were made because the
baseline-corrected UV absorption spectra of bergamottin, DHB, and FC726
were identical (not shown) and because mass spectral analysis demonstrated
that FC726 is a dimer (see Results).
Quantitation of DHB in Grapefruit Juice Preparations (data in table 1).
With fresh grapefruit, samples were prepared by hand-squeezing 3–5 fruits.
Juice was homogenized with a teflon-type tissue grinder (Wheaton Instru-
ments, Millville, NJ) prior to analysis. The samples were extracted with
methylene chloride and the content of DHB was assayed by HPLC as previ-
ously described (14).
In vivo study. Endoscopic duodenal biopsies were obtained from a healthy
adult female volunteer before and 4 hr after drinking one 8-ounce glass of
TABLE 1
Concentration of furanocoumarins in grapefruit products
Product
Bergamottin DHB 69-Epoxybergamottin FC726
Concentration (mM)
Grapefruit oil (Berje´) 2600 1400 15,700 16.3
Grapefruit oil (Spectrum) 2500 4300 22,400 28.9
Florida white grapefruita 17.9 (1.1 mg) 15.2 (1.0 mg) 7.4 (0.5 mg) 0.2 (31 mg)
White grapefruit juice concentrate (reconstituted)b 4.3 (0.3 mg) 27.4 (2.4 mg) 0.1 (9 mg) 0.1 (10 mg)
a Numbers given reflect concentrations in the fruit (see Methods). Numbers in parentheses indicate the total amounts present in a single fruit.
b Numbers reflect final concentrations in appropriately reconstituted juice. Numbers in parentheses indicate the total amounts calculated to be present in an
8-ounce glass of regular strength grapefruit juice prepared from concentrate.
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reconstituted Kroger brand frozen grapefruit juice concentrate. This study was
approved by the University of Michigan Institutional Review Board. The
biopsies were subjected to immunoblot analysis as previously described (12).
Cell Culture. The Caco-2 cell clone P27.7 was cultured using previously
described conditions under which the cells express metabolically active
CYP3A4 (21).
Incubations (4 hr) with apically administered midazolam (4 mM) were
performed. Grapefruit oil and constituent compounds or vehicle (absolute
ethanol) were administered concurrently with midazolam to the apical me-
dium. After the incubations, the medium from the apical and basolateral
compartments of each culture were combined and assayed for the concentra-
tion of 19-hydroxymidazolam, and the rates of 19-hydroxymidazolam forma-
tion were calculated. One culture for each treatment was used for catalytic
activity and immunoblots. A parallel set of cultures at the highest concentra-
tions of grapefruit oil, DHB, FC726, and ketoconazole was used for paraffin
embedding and preparation of H&E stained sections.
Immunoblots. Immunoblot analysis of intestinal biopsies and Caco-2 cells
was performed as previously described (12, 21). Intestinal biopsy content of
CYP3A4 was expressed as a ratio to the constitutively expressed enterocyte
protein villin (12, 22). Immunoblots were repeated twice, and representative
blots are shown. Protein loading for intestinal biopsy homogenates was: 15 mg.
Protein loading for Caco-2 cells was: CYP3A and villin, 5 mg; CYP1A1 and
CYP2D6, 25 mg.
1*-Hydroxymidazolam Assay. Quantitation of 19-hydroxymidazolam in
Caco-2 culture medium was accomplished by gas chromatography/negative
ion chemical ionization—selective ion mass spectrometry as previously de-
scribed (21).
Expression of CYP3A4 in E. Coli and Purification. A full length
CYP3A4 cDNA inserted into the pCW vector was obtained from Dr. Ronald
W. Estabrook (University of Texas Southwestern Medical Center, Dallas, TX).
The CYP3A4-containing vector was transfected into MV1304 cells. The
transformed E. coli were grown in modified Terrific Broth, and the expression
of CYP3A4 was induced by addition of 1 mM isopropyl b-D-thiogalactoside.
d-Aminolevulinic acid (0.5 mM) was added to increase heme synthesis. After
lysozyme treatment and sonication of the bacteria, the membrane fraction was
isolated by differential centrifugation. CYP3A4 was purified to homogeneity
from detergent solubilized membranes on a DE52 column as previously
described (23).
DHB-Mediated Inactivation of CYP3A4 in a Reconstituted System.
CYP3A4 (0.5 nmol) was reconstituted with 20 mg of a mixture (1:1:1) of
L-a-dilauroyl- and L-a-dioleyl-sn-glycero-3-phosphocholines and phosphati-
dyl serine, 200 mg of cholic acid, 1 nmol of NADPH-cytochrome P450
reductase, 0.5 nmol of cytochrome b5, 500 U of catalase, 2 mmol of glutathi-
one, 30 mM MgCl2, 0.5 mM EDTA, and 20% (v/v) glycerol in a final volume
of 1 ml of 50 mM Hepes buffer (pH 7.5). Reactions with various concentra-
tions of DHB, performed at 37°C for the times indicated, were initiated by
addition of 1 mM NADPH and were terminated on ice. At each time point, 50
ml of the incubation mixture was removed and diluted to 1 ml with 50 mM
Hepes buffer (pH 7.5) containing 200 mM testosterone, 500 U of catalase, 2
mmol of glutathione, 30 mM MgCl2, 0.5 mM EDTA, and 20% (v/v) glycerol.
Following a 10-min incubation, the concentration of 6b-hydroxytestosterone
formed was determined by HPLC on a C18 column [Microsorb-MV (Rainin,
Woburn, MA), 5 mm, 4.6 3 15 cm] eluted with a mobile phase of 65%
methanol at a flow rate of 1 ml/min with monitoring of the eluate by UV
detection at 254 nm.
Results
To determine whether a single glass of grapefruit juice decreases
enterocyte CYP3A4, small bowel mucosal biopsies were obtained
from a volunteer before and after consumption of a single 8-ounce
glass of regular strength grapefruit juice. As shown in fig. 1, drinking
the juice resulted in a 47% decrease in enterocyte CYP3A4 concen-
tration at 4 hr, indicating that this was a rapid effect.
When grapefruit oil was added to the apical medium of Caco-2
cells, a concentration-dependent fall in CYP3A4 catalytic activity
(midazolam 19-hydroxylase) with 97% inhibition at the highest con-
centration (0.1% v/v) was observed (fig. 2B). The estimated IC50 of
grapefruit oil for loss of midazolam 19-hydroxylase activity in the
Caco-2 cells was 0.0015%. The decrease in catalytic activity was
accompanied by a fall in immunoreactive CYP3A4 protein. The
highest concentration of grapefruit oil (0.1%) resulted in approxi-
mately a 50% reduction in CYP3A4 immunoreactive protein.
Fraction 39 from the HPLC fractionation of grapefruit juice showed
one peak by HPLC that had an electronic absorption spectrum with
absorption maxima at 225, 250, and 310 nm, which is consistent with
a furanocoumarin (also called psoralen). Mass spectral analyses
showed a molecular ion of m/z 726 and a daughter ion spectrum
consistent with a psoralen dimer [m/z (relative abundance)]: 203
(100%); 153 (90%); 215 (76%); 135 (48%); 355 (26%); 337 (25%);
709 (12%); 107 (12%); and 373 (4%). Based on electronic absorption
and mass spectra, the active component in fraction 39 was identified
as a geranyloxypsoralen ether dimer with mass 726 g/mol and was
designated FC726. Kinetic analysis of incubations with human liver
microsomes showed that FC726 was an inhibitor of CYP3A4-medi-
ated taxol metabolite B formation with an IC50 value of less than 0.5
mM. Numerous other furanocoumarin or psoralen compounds isolated
from grapefruit juice were also found to inhibit CYP3A4 and
CYP2C8 activities but were excluded from further consideration
because of their lack of selectivity for CYP3A4.
The effects of grapefruit oil on CYP3A4 catalytic activity and
immunoreactive protein were reproduced by DHB and FC726 (fig. 2C
and 2D, respectively). The calculated IC50 for loss of midazolam
19-hydroxylase activity was 1.04 mM for DHB and 1.00 mM for
FC726. At the highest concentration examined (10 mM), DHB and
FC726 decreased immunoreactive CYP3A4 by approximately 40%
and 50%, respectively. Immunoreactive CYP2D6 and CYP1A1 con-
centrations were not reduced by any of the treatments (fig. 2B, C, D),
and the concentration of CYP1A1 may have increased.
Ketoconazole produced a concentration-dependent inhibition of
midazolam 19-hydroxylase activity (fig. 2E) with a calculated IC50 of
TABLE 2
Concentration of 69,79-dihydroxybergamottin in grapefruit juice from various sources
Product N Mean Conc. (mM) Range (mM)
Florida white grapefruit commercially squeezed (Tropicana Golden) 5 28.5 15.3–43.3
Florida white grapefruit fresh squeezed by hand 9 23.1 14.0–33.6
Florida pink grapefruit commercially squeezed (Tropicana Ruby Red) 5 12.9 10.8–14.5
Florida pink grapefruit fresh squeezed by hand 8 16.4 1.4–45.2
Texas Rio Star Grapefruit fresh squeezed by hand 5 19.6 4.6–30.9
Frozen concentrated grapefruit juice reconstituted (various brands) 6 44.4 33.1–58.4
The concentration of 69,79-dihydroxybergamottin was determined by HPLC in methylene chloride extracts of commercially prepared grapefruit juices and
juices hand squeezed from fruits obtained at local markets. N 5 number of different lots (commercially squeezed juices), sources of fruit (fresh squeezed juices),
or brands (frozen concentrate).
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0.27 mM. In contrast to the effects of the furanocoumarins, however,
the CYP3A4 concentration did not decrease and may have increased
(fig. 2E).
Light microscopic examination of H&E stained sections of Caco-2
cells exposed for 4 hr to 0.1% grapefruit oil, 10 mM DHB, 10 mM
FC726, or 10 mM ketoconazole showed no signs of cytotoxicity (data
not shown).
Limonene, a major constituent of grapefruit oil (24), and decanal,
one of the principal aldehydes contained in grapefruit oil (24), in
concentrations as high as 100 mM did not inhibit CYP3A catalytic
activity and did not affect the concentration of CYP3A protein in the
Caco-2 cells (data not shown).
To examine further the interaction between furanocoumarins and
CYP3A4, kinetic studies were conducted with recombinant CYP3A4
and DHB. As shown in fig. 3, DHB caused a time- and concentration-
dependent inactivation of CYP3A4. The inactivation exhibited pseu-
do-first order kinetics. Linear regression analysis of the data in fig. 3
was used to determine the initial rate constants of inactivation (Kobs).
The maximal rate constant (kinact) and the concentration of inactivator
required for half-maximal rate of inactivation (KI) were determined to
be 0.16 min21 and 59 mM, respectively, by double-reciprocal plotting
of the values of Kobs and DHB concentrations (25). These results
demonstrate that DHB is a mechanism-based inactivator of CYP3A4
(25). The inactivation event appeared to occur at the active site
because the inactivation rate was not affected by the presence of 2 or
3 mM glutathione in the incubation system. As can be seen from the
ordinate in fig. 3, DHB-mediated inhibition of CYP3A4 activity did
not require pre-incubation with NADPH. The maximum loss in ac-
tivity after pre-incubation without NADPH (48.6%) was seen follow-
ing incubation with 100 mM DHB. Sufficient quantities of FC726
were not available to perform similar studies.
We next determined the concentrations of bergamottin, DHB, 69-
epoxybergamottin, and FC726 in two samples of grapefruit oil, care-
fully excised grapefruit sections, and reconstituted frozen grapefruit
juice concentrate. As shown in table 1, all of the furanocoumarins
were present in all of the items examined but were most concentrated
in the oil. DHB was more concentrated in the reconstituted juice than
in the fresh fruit. In contrast, 69-epoxybergamottin, bergamottin, and
FC726 were more concentrated in the fresh fruit than in the reconsti-
tuted juice. Because DHB was the most concentrated furanocoumarin
in the juice, its concentration was determined in a variety of commer-
cial grapefruit juices and in hand-squeezed grapefruit juice. As shown
in table 2, the concentration of DHB varied considerably among
juices, but was generally highest in the reconstituted frozen concen-
trate.
Discussion
Recurrent grapefruit juice ingestion has been shown to result in
selective loss of CYP3A4 protein but not mRNA in small intestinal
epithelial cells (12). This loss of enzyme is presumed to account, at
least in part, for grapefruit juice-drug interactions (12). In the studies
presented herein, we have shown that the in vivo fall in intestinal
CYP3A4 is rapid and occurs within 4 hr after ingestion of a single
glass of the juice (fig. 1). In addition, this effect of grapefruit juice was
also observed in vitro in Caco-2 cells exposed to grapefruit oil, DHB,
and a second furanocoumarin present in grapefruit juice (FC726) (fig.
2). Each of these substances produced a dose-dependent fall in both
CYP3A4 immunoreactive protein and catalytic activity (fig. 2). As
previously demonstrated in vivo (12), the effect was selective in that
no reduction in CYP1A1 or CYP2D6 proteins was observed (fig. 2).
These data support the idea that furanocoumarins are the major active
ingredients responsible for grapefruit juice-drug interactions.
Our data from incubations of recombinant CYP3A4 with DHB
support the idea that the effect of furanocoumarins in grapefruit juice
results, at least in part, from mechanism-based inactivation of
CYP3A4 (fig. 3). Mechanism-based inactivation has been shown to
result in accelerated degradation of a CYP3A enzyme in rat liver (26).
The establishment of DHB as a mechanism-based inactivator of
CYP3A4, therefore, supports the prior suggestion that the loss of
CYP3A4 from enterocytes produced by grapefruit juice in vivo may
result from accelerated degradation of the enzyme (12). Mechanism-
based inactivation and loss of enzyme may account for the prolonged
($ 24 hr) effect of grapefruit juice on oral felodipine kinetics (27).
It should be noted that concentration-dependent inhibition of
CYP3A4 activity was also observed without pre-incubation with DHB
and NADPH (fig. 3). A likely explanation is that DHB, carried over
to the second reaction mixture, is a potent competitive inhibitor of
CYP3A4. DHB was originally identified as a possible active compo-
nent in grapefruit juice because of its ability to competitively inhibit
a rat CYP3A enzyme (14). In addition, we have found that DHB is
metabolized to several hydroxylated products by CYP3A4,2 indicat-
ing that it is a substrate for the enzyme. Competitive inhibition may in
part account for the finding that greater than 90% inhibition of
CYP3A4 catalytic activity occurred in Caco-2 cells in which the
content of immunoreactive protein had fallen by no more than 60%
(fig. 2). However, a delay between mechanism-based inactivation and
subsequent enzyme degradation may be expected and could also
contribute to this disparity.
Our data also support the conclusion that DHB is the major com-
pound responsible for drug interactions caused by reconstituted frozen
concentrate, the form of grapefruit juice most commonly consumed. It
was the major furanocoumarin identified in frozen concentrate (table
1). Moreover, the concentration of DHB present in all of the grapefruit
juice preparations analyzed (tables 1 and 2) exceeded the IC50 for
midazolam 19-hydroxylation determined in the Caco-2 cells (approx-
imately 1.0 mM). In contrast, DHB does not appear to be the major
responsible component in grapefruit oil. Grapefruit oil exists in nature
in the peel of the fruit and is frequently added as a flavor enhancer
during commercial preparation of frozen grapefruit juice concentrate.
The IC50 of grapefruit oil was determined to be approximately
0.0015%. Given the concentration of DHB determined in the oil used
in the cell culture experiments (4.3 mM), the concentration of DHB
was approximately 0.06 mM in 0.0015% oil. This concentration is less
than 10% of the 1.0 mM IC50 estimated for DHB in the cells. It should
be noted that the concentration of 69-epoxybergamottin measured in
2 P. F. Hollenberg and K. He, data not shown, 1997.
FIG. 1. Effect of grapefruit juice on intestinal CYP3A4.
Endoscopic duodenal biopsies were obtained from a healthy adult volunteer
before (Pre) and 4 hr after (Post) drinking an 8-ounce glass of grapefruit juice.
The biopsies were homogenized and subjected to immunoblot analysis to
determine CYP3A4 and villin concentrations. Villin, a constitutively expressed
enterocyte protein, served as a control for the relative contribution of entero-
cytes to the biopsy mass (12, 22).
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the oil (22.4 mM, table 1) would result in a concentration of approx-
imately 0.3 mM in 0.0015% oil. If 69-epoxybergamottin is an inhibitor
of CYP3A4 and has a potency comparable to that of DHB, the sum of
the epoxide and DHB concentrations could probably account for most
of the CYP3A4 inhibition produced by the oil.
The furanocoumarin dimer (FC726) we isolated from the juice
appears to be a minor constituent, unlikely to substantially contribute
to grapefruit juice-drug interactions. In our early studies, the concen-
tration of this and of several other furanocoumarin compounds
seemed to be more substantial relative to DHB. It was later deter-
mined, however, that this resulted from our initial use of hexane for
extraction. We found that DHB is not well extracted by hexane and its
abundance in the juice was not evident until a more polar solvent
(methylene chloride or chloroform) was used. We remain interested in
FC726 because it is more selective as an inhibitor of CYP3A4 than are
other furanocoumarins present in grapefruit juice.
The addition of grapefruit oil to frozen concentrate presumably
accounts for the observation that reconstituted juice generally has
higher concentrations of DHB than does fresh juice (table 2). The
virtual absence of the epoxide from the concentrate (table 1) was
unexpected. We have found that the epoxide is converted to DHB in
the presence of citric acid3 and speculate that this conversion occurs
during commercial processing of the juice.
Furanocoumarins require light for their synthesis (28), and it was
therefore possible that grapefruit oil (or the exterior portions of the
peel) might be the sole source of these compounds in grapefruit juice.
Although grapefruit oil contained the highest concentrations of
furanocoumarins, these compounds were present in the fruit itself
(table 1). Our data suggest that a whole grapefruit consumed as is
customary in sections cut from halved fruit results in ingestion of
approximately 1 mg of DHB (table 1). This amount corresponds
roughly to that present in 3 ounces of an average reconstituted juice.
This suggests that drinking freshly squeezed grapefruit juice or eating
the fruit whole should produce an interaction with drugs similar to that
observed with consumption of the reconstituted concentrate, although
probably of lower magnitude. The clinical effect of fresh squeezed
juice or the fruit itself has not yet been studied to our knowledge.
A final point is the variability in the concentration of DHB we
determined in different brands of grapefruit juice and in different lots
of the same brand of juice (table 2). This indicates that variability in
the extent of the grapefruit juice effect can be expected with the
consumption of different grapefruit juice preparations. This needs to
be taken into account when comparing data from different institutions
and indicates that the concentrations of the active ingredients, at least
DHB, should probably be standardized in future studies.
3 P. B. Watkins and M. E. Fitzsimmons, unpublished observations, 1997.
FIG. 2. Effect of grapefruit oil and constituent compounds on CYP3A4 catalytic activity and expression of various cytochromes P450.
The Caco-2 cell clone P27.7 was cultured using previously described conditions under which the cells express metabolically active CYP3A4 (21). Shown are
rates of midazolam 19-hydroxylation by the cultured cells and representative immunoblots of cell homogenates probed with antibodies of the indicated
specificities. Veh., vehicle; Gf, grapefruit; DHB, 69,79-dihydroxybergamottin; keto, ketoconazole; 19-OH-MDZ, 19-hydroxymidazolam. CYP3A4 concentrations were
determined by computer aided densitometry using serial dilutions of purified CYP3A4 protein added in a second loading to the gels. Vehicle control lanes contained
20 fmol CYP3A4/mg of total protein. The CYP3A4 concentration decreased to 10 fmol CYP3A4/mg after exposure to 0.1% grapefruit oil, a 50% decrease. Thus, visual
interpretation of immunoblots developed with ECL overestimates actual changes in CYP3A4 protein concentrations.
FIG. 3. Time- and concentration-dependent inactivation of the testosterone
6b-hydroxylase activity of CYP3A4 by 69,79-dihydroxybergamottin (DHB).
Recombinant CYP3A4 was pre-incubated with various concentrations of
DHB in a reconstituted system for the times indicated (see Methods). A 50 ml
sample was then removed and incubated with testosterone in a reconstituted
system. After a 10-min incubation, the rate of formation of 6b-hydroxytestos-
terone was measured. The initial concentrations of DHB in the incubations
were 0 mM (M), 25 mM ({), 50 mM (E), and 100 mM (), respectively.
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In summary, at least two distinct furanocoumarins present in grape-
fruit and grapefruit juice are capable of decreasing CYP3A4 activity
and reducing cellular concentrations of this enzyme. The presentfind-
ings support 69,79-dihydroxybergamottin as the major furanocoumarin
responsible for these effects after consumption of reconstituted frozen
concentrate.
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